Pioglitazone alters monocyte populations and stimulates recent thymic emigrants in the BBDZR/Wor type 2 diabetes rat model.
CONCLUSIONS: We show for the first time that Pio treatment significantly suppresses the systemic inflammatory status in the BBDZR/Wor type 2 diabetes rat model by the selective growth of newly differentiated CD3(+) T cells and by increasing CD3(+)IL-4 production in immigrant spleen lymphocytes.
PMID: 26336514 [PubMed - as supplied by publisher] (Source: Diabetes Metab)
Source: Diabetes Metab - September 4, 2015 Category: Endocrinology Authors: Gao BT, Lee RP, Jiang Y, Steinle JJ, Morales-Tirado VM Tags: Diabetol Metab Syndr Source Type: research
Onset of Graves' disease during long-term immunosuppressive therapy in a patient with membranous nephropathy.
Abstract
A 67-year-old man was referred to our department for thyrotoxicosis with intermittent palpitation and 4-kg weight loss during the previous month. At the first visit, the patient was treated with cyclosporine A (CyA) for membranous nephropathy during the last 3 years and 8 months. Laboratory studies revealed that the serum TSH level was <0.005 μU/ml, and free thyroxine (fT4) and triiodothyronine (fT3) levels were elevated at 2.76 ng/dl and 5.96 pg/ml respectively. Anti-TSH receptor antibody (TRAb) level was increased at 26.4%. A clinical diagnosis of Graves' hyperthyroidism was given, and...
Source: Diabetes Metab - September 4, 2015 Category: Endocrinology Authors: Iwasaki H Tags: Endocrinol Diabetes Metab Case Rep Source Type: research
IWGDF Guidance on the prevention of foot ulcers in at-risk patients with diabetes.
PMID: 26334001 [PubMed - as supplied by publisher] (Source: Diabetes Metab)
Source: Diabetes Metab - September 3, 2015 Category: Endocrinology Authors: Bus SA, van Netten JJ, Lavery LA, Monteiro-Soares M, Rasmussen A, Jubiz Y, Price PE, International Working Group on the Diabetic Foot (IWGDF) Tags: Diabetes Metab Res Rev Source Type: research
Prevention and management of foot problems in diabetes: a summary guidance for daily practice 2015, based on the IWGDF guidance documents.
PMID: 26335366 [PubMed - as supplied by publisher] (Source: Diabetes Metab)
Source: Diabetes Metab - September 3, 2015 Category: Endocrinology Authors: Schaper NC, Van Netten JJ, Apelqvist J, Lipsky BA, Bakker K, International Working Group on the Diabetic Foot (IWGDF) Tags: Diabetes Metab Res Rev Source Type: research
Tissue IGF-I measured by microdialysis reflect body glucose utilization after rhIGF-I injection in type 1 diabetes.
CONCLUSION: We demonstrate that md-IGF-I measurements are valid and physiologically relevant by reflecting rhIGF-I induced glucose uptake. Future studies should elucidate the role of local tissue IGF-I in diabetic vascular complications.
PMID: 26331550 [PubMed - as supplied by publisher] (Source: Diabetes Metab)
Source: Diabetes Metab - September 2, 2015 Category: Endocrinology Authors: Ekström K, Pulkkinen MA, Carlsson-Skwirut C, Brorsson AL, Ma Z, Frystyk J, Bang P Tags: J Clin Endocrinol Metab Source Type: research
IWGDF guidance on the diagnosis, prognosis and management of peripheral artery disease in patients with foot ulcers in diabetes.
PMID: 26332424 [PubMed - as supplied by publisher] (Source: Diabetes Metab)
Source: Diabetes Metab - September 2, 2015 Category: Endocrinology Authors: Hinchliffe RJ, Brownrigg JR, Apelqvist J, Boyko EJ, Fitridge R, Mills JL, Reekers J, Shearman CP, Zierler RE, Schaper NC, International Working Group on the Diabetic Foot (IWGDF) Tags: Diabetes Metab Res Rev Source Type: research
Efficacy and Safety of Bromocriptine-QR in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
The objective of this study is to assess the efficacy and safety of bromocriptine-QR in adults with type 2 diabetes mellitus based on randomized controlled trials published in peer-reviewed journals or as abstracts. We performed a comprehensive literature search of MEDLINE, Pubmed, Web of Science, EMBASE, and the Cochrane Library up to May 2015. Randomized controlled trials of bromocriptine-QR therapy in type 2 diabetes mellitus were eligible. Two reviewers independently assessed the eligibility of trials based on predefined inclusion criteria. Information was collected concerning basic study data, patient characteristics,...
Source: Diabetes Metab - September 2, 2015 Category: Endocrinology Authors: Liang W, Gao L, Li N, Wang B, Wang L, Wang Y, Yang H, You L, Hou J, Chen S, Zhu H, Jiang Y, Pan H Tags: Horm Metab Res Source Type: research
A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide.
CONCLUSION: Dulaglutide is effective in the treatment of patients with type 2 diabetes but we need long follow-up data for safety concerns.
PMID: 26316788 [PubMed] (Source: Diabetes Metab)
Source: Diabetes Metab - September 1, 2015 Category: Endocrinology Authors: Gurung T, Shyangdan DS, O'Hare JP, Waugh N Tags: Diabetes Metab Syndr Obes Source Type: research
Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD-scid IL-2rg(null) RIP-DTR mice engrafted with human islets.
CONCLUSION: Diabetic human islet-engrafted immunodeficient mice treated with lixisenatide show improved restoration of normoglycemia, human plasma insulin, and glucose tolerance compared to vehicle-treated mice engrafted with the same donor islets. Because the proliferative capacity of human beta cells is limited, improved beta-cell survival coupled with enhanced beta-cell function following lixisenatide treatment may provide the greatest benefit for diabetic patients with reduced functional islet mass.
PMID: 26316789 [PubMed] (Source: Diabetes Metab)
Source: Diabetes Metab - September 1, 2015 Category: Endocrinology Authors: Yang C, Loehn M, Jurczyk A, Przewozniak N, Leehy L, Herrera PL, Shultz LD, Greiner DL, Harlan DM, Bortell R Tags: Diabetes Metab Syndr Obes Source Type: research
Knockout of Vdac1 activates hypoxia-inducible factor through reactive oxygen species generation and induces tumor growth by promoting metabolic reprogramming and inflammation.
CONCLUSIONS: Metabolic reprogramming in cancer cells may be regulated by VDAC1 through vascular destabilization and inflammation. These findings provide new perspectives into the understanding of VDAC1 in the function of mitochondria not only in cancer but also in inflammatory diseases.
PMID: 26322231 [PubMed] (Source: Diabetes Metab)
Source: Diabetes Metab - September 1, 2015 Category: Endocrinology Authors: Brahimi-Horn MC, Giuliano S, Saland E, Lacas-Gervais S, Sheiko T, Pelletier J, Bourget I, Bost F, Féral C, Boulter E, Tauc M, Ivan M, Garmy-Susini B, Popa A, Mari B, Sarry JE, Craigen WJ, Pouysségur J, Mazure NM Tags: Cancer Metab Source Type: research
Postmenopausal Endocrinology.
PMID: 26316250 [PubMed - in process] (Source: Diabetes Metab)
Source: Diabetes Metab - September 1, 2015 Category: Endocrinology Authors: LeRoith D Tags: Endocrinol Metab Clin North Am Source Type: research
Gestational Diabetes Associated with a Novel Mutation (378-379insTT) in the Glycerol Kinase Gene.
We report a male patient with GKD and a novel insertion of TT in exon 5 at position 378 of the GK cDNA (378-379insTT). This resulted in a premature stop codon and 0.8% normal GK activity. The mother is a carrier for this mutation and had gestational diabetes requiring insulin during this pregnancy but not in her previous pregnancy. Given the association between GKD and type 2 diabetes mellitus, it is interesting that the mother had gestational diabetes while carrying an affected fetus. Therefore, GKD is another disease where there may be a maternal-fetal interaction based on genotype. Further investigations may help elucid...
Source: Diabetes Metab - August 27, 2015 Category: Endocrinology Authors: Zhang YH, Van Hove JL, McCabe ER, Dipple KM Tags: Mol Genet Metab Rep Source Type: research
News and Views.
PMID: 26294357 [PubMed - in process] (Source: Diabetes Metab)
Source: Diabetes Metab - August 22, 2015 Category: Endocrinology Authors: Idris I Tags: Diabetes Obes Metab Source Type: research
Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins.
The objective of this review is to highlight the advantages of mono- and combination therapy with pioglitazone in comparison with gliptins and to underline the inconsistencies in the medicinal and reimbursement policy in Bulgaria.
PMID: 26288659 [PubMed] (Source: Diabetes Metab)
Source: Diabetes Metab - August 22, 2015 Category: Endocrinology Authors: Filipova EP, Uzunova KH, Vekov TY Tags: Diabetol Metab Syndr Source Type: research
Results of glycated hemoglobin during treatment with insulin analogues dispensed in the public health system of Federal District in Brazil.
CONCLUSION: The low number of patients using insulin analogues in the target group, considered to be in good control, implies the need to reevaluate both level of patients self-care knowledge and glucose monitoring prior their inclusion in the insulin analogue dispense program. Reinforcement and training of health professional teams in enrollment procedures should be on mandatory basis to avoid protocol failure or deviations.
PMID: 26288660 [PubMed] (Source: Diabetes Metab)
Source: Diabetes Metab - August 22, 2015 Category: Endocrinology Authors: Leite EB, Pedrosa HC, Casulari LA Tags: Diabetol Metab Syndr Source Type: research
